On this page
Key takeaways
• Senolytic activity — the flagship claim — is well established in mice and human tissue explants (1) but has not been demonstrated in any published human randomised trial.
• Frailty and muscle preservation rest on strong 2025 mouse work showing effect sizes equivalent to gold-standard senolytic interventions (2). Human replication (AFFIRM, NCT03430037) has been unreported since 2018 (5).
• Neuroprotection and cognitive benefit rest on more than a decade of Salk Institute mouse work (3,7). No human RCT has reported a cognitive endpoint for oral fisetin.
• Skin and hair rest on individual mouse studies with mechanistically coherent findings — UVB photoprotection (9) and topical TERT-mediated hair growth (8). Human trials for either indication are absent.
• Inflammation, allergies, and joint pain rest on broad anti-inflammatory pharmacology in cells and animals. Human data are limited to an uncontrolled long-COVID case series.
• Bioavailability is the shared caveat. Unformulated oral fisetin produces plasma concentrations 30–150-fold below the in vitro senolytic window (4). Every benefit claim must be read against this ceiling.
Quick answer
Fisetin is a genuinely interesting molecule with a mostly preclinical evidence base. It has strong mouse evidence for clearing senescent cells, preserving muscle function in ageing, protecting neurons, and reducing inflammatory signalling. It has minimal human clinical trial evidence for any of these outcomes. Anyone taking fisetin in 2026 is betting on translation from mice to humans — a reasonable bet, but not the same thing as taking a supplement with proven human benefit. This article walks through each benefit claim, names the evidence tier, and identifies the honest caveat each indication carries. For the complete clinical picture, see our full clinician’s guide.
How to read this article — the evidence tier framework
Every benefit claim below is graded against a four-tier framework we apply consistently across the site.
|
Tier |
Meaning |
Where fisetin sits (in most indications) |
|
Tier 1 |
Meta-analysis or multiple consistent human RCTs |
Not yet reached for any fisetin indication |
|
Tier 2 |
A single anchor RCT with independent replication |
Not yet reached |
|
Tier 3 |
Strong preclinical evidence (mouse, cell); human trials ongoing but unreported |
Where most fisetin claims sit |
|
Tier 4 |
Mechanistic or theoretical only |
Where the weaker fisetin claims sit |
This is not a trick framework — it is the same framework we apply to every longevity supplement on the site. It exists because Tier 3 evidence is genuinely interesting but is not the same thing as Tier 1. When a product page describes benefits as if they are settled human clinical facts, it is usually collapsing a Tier 3 case into Tier 1 language.
Senescent cell clearance — the flagship claim (Tier 3)
The 2018 Yousefzadeh paper is the founding evidence for fisetin as a senolytic (1). In cell culture, fisetin at 5 μM selectively induced apoptosis in senescent mouse embryonic fibroblasts, senescent IMR90 human lung fibroblasts, and senescent HUVEC endothelial cells while sparing healthy dividing cells of the same type. In mice, acute oral gavage at 100 mg/kg for five days reduced p16-positive cell burden in adipose tissue, spleen, kidney, and CD3-positive peripheral T cells. Chronic chow-feeding from 85 weeks of age (equivalent to old age in mice) extended median lifespan modestly.
The honest caveat. No published human RCT has reported that oral fisetin reduces any biomarker of senescent-cell burden in any tissue. The Mayo Clinic AFFIRM trial (NCT03430037) has been recruiting since 2018 and remains unreported eight years later (5). The COVID-FIS trial (NCT04537299) posted topline results to ClinicalTrials.gov in August 2025, but the peer-reviewed manuscript has not appeared (6). The senolytic biology in mice is real; the senolytic effect in humans is currently untested at any published dose. The full story is in our dedicated senolytic article.
Frailty and muscle preservation (Tier 3, strong)
This is where the recent preclinical evidence is strongest. Murray and colleagues (Aging Cell, 2025) supplemented 24-month-old mice with intermittent fisetin at doses equivalent to the human 20 mg/kg × 2 days protocol used in the Mayo Clinic trials (2). Fisetin preserved grip strength, improved gait speed, and reduced senescent-cell markers in skeletal muscle tissue. The effect size was statistically indistinguishable from genetic clearance of p16-positive cells — the gold-standard preclinical intervention — and from the small-molecule combination dasatinib plus quercetin. Head-to-head equivalence with genetic clearance is a striking result for a natural compound.
The honest caveat. The corresponding human trials are all in progress. AFFIRM specifically enrols frail post-menopausal women (5). PROFFi (NCT06113016) enrols breast cancer survivors at frailty risk. Hvidovre Fisetin HIGH (NCT06431932) enrols older multimorbid patients. None have reported. Until they do, the muscle-preservation claim is a strong preclinical hypothesis, not a documented human benefit. See our dedicated fisetin for muscle and frailty article for the trial pipeline.
Cognitive function and neuroprotection (Tier 3)
The neuroprotection literature is genuinely substantial. Currais and colleagues supplemented the rapidly-aging SAMP8 mouse model with fisetin from 4 months of age and reported preserved cognitive function on multiple behavioural tests along with reduced markers of oxidative stress and inflammation in the brain (3). Pamela Maher’s Salk Institute group has extended this work across mouse models of Alzheimer’s, Parkinson’s, Huntington’s, and stroke (7). The mechanisms include Nrf2 activation, glutathione support via cystine uptake, and suppression of neuroinflammation. Fisetin crosses the blood-brain barrier in mice.
The honest caveat. No published human RCT has demonstrated that oral fisetin improves any cognitive endpoint. The Mayo Clinic 2024 long-COVID series described 28 of 44 patients (64%) reporting subjective cognitive improvement after fisetin, but the series was uncontrolled, unblinded, and has not been peer reviewed. Cognitive benefits in a human capsule taker are extrapolation from mouse models, not documented outcome. See our dedicated brain and cognition article for the detailed evidence review.
Inflammation, allergies, and SASP suppression (Tier 3)
Fisetin’s anti-inflammatory identity is broadly established in cell and animal models. It suppresses NF-κB signalling, reduces the transcription of IL-6, TNF-α, and IL-1β, and — in senescent tissue specifically — suppresses the Senescence-Associated Secretory Phenotype (SASP), the pro-inflammatory secretome that drives inflammaging (1,7). Individual studies have demonstrated benefit in mouse models of pulmonary fibrosis (10), mast cell activation, and allergic inflammation. The 2024 Mayo Clinic long-COVID series described reductions in some inflammatory markers, though this was uncontrolled data.
The honest caveat. Whether daily 400–800 mg fisetin in a healthy adult produces detectable changes in systemic inflammatory markers (hs-CRP, IL-6) has not been formally tested in a controlled trial. Readers who want to verify this benefit personally should track hs-CRP before and after a defined trial window. Our inflammation and joints article covers the individual indications.
Skin — antioxidant, photoprotective, and dermal senolytic (Tier 3)
Wu and colleagues applied fisetin topically to hairless mice exposed to chronic UVB irradiation and reported reduced erythema, reduced wrinkle formation, reduced epidermal hyperplasia, and increased collagen content in the dermis (9). The mechanism worked through Nrf2 activation and suppression of matrix metalloproteinase upregulation. This is a preclinical result but a mechanistically coherent one that aligns with fisetin’s general antioxidant and anti-inflammatory pharmacology.
The honest caveat. Human trial data for oral or topical fisetin on skin outcomes is absent. Bioavailability of oral fisetin to dermal tissue at supplement doses is not characterised. Topical fisetin formulations are not standardised — the concentration, vehicle, and delivery matrix vary widely across products. Our dedicated fisetin for skin article walks through both oral and topical evidence.
Hair growth and grey hair (Tier 3–4, mixed)
Sasaki and colleagues identified fisetin in a targeted screen of food compounds that could activate the promoter of telomerase reverse transcriptase (TERT) in keratinocytes — a marker relevant to hair follicle stem cell longevity (8). In vivo, topical fisetin applied to mouse dorsal skin at 1% w/v in 50% ethanol promoted hair growth over 12 days. A follow-up paper demonstrated that fisetin-treated keratinocytes released exosomes that promoted hair growth in a paracrine manner.
The honest caveat. Human trial data are absent. Grey hair reversal reports are anecdotal, mostly from longevity forums, and are not supported by controlled trials. The mouse work used topical application; the marketing claim usually implies oral capsules. These are not the same intervention. See our fisetin for hair growth and grey hair article for the honest evidence review.
Metabolic health and blood sugar (Tier 3–4)
Preclinical work in streptozotocin-induced diabetic rats showed that fisetin at 10 mg/kg reduced fasting glucose, improved insulin sensitivity, and reduced HbA1c-equivalent markers (12). Mechanistically, fisetin has been reported to activate AMPK, improve mitochondrial function, and reduce hepatic gluconeogenesis in mouse models.
The honest caveat. No human RCT has demonstrated meaningful glycaemic effects from fisetin at supplement doses. Patients with diabetes on metformin, SGLT2 inhibitors, or other glucose-lowering therapy should not substitute fisetin for their prescribed medication. The metabolic benefit claim is a legitimate preclinical hypothesis that has not translated to human evidence.
Reproductive health, fertility, and ovarian ageing (Tier 3–4, emerging)
A 2025 review documented fisetin’s pleiotropic effects on women’s reproductive tissue in preclinical models — modulation of ovarian follicular ageing, fibrosis in endometrial and uterine tissue, and hormonal signalling (11). This is an emerging area with genuine mechanistic interest but no controlled human trial data.
The honest caveat. Fisetin should not be taken during pregnancy or breastfeeding without obstetric consultation. Its effects on fertility outcomes in humans are entirely unstudied. Our dedicated pregnancy article covers this carefully.
Healthy ageing and lifespan extension (Tier 3, single mouse study)
The Yousefzadeh 2018 paper reported that fisetin-supplemented chow, started at 85 weeks of age, extended median lifespan in wild-type mice (1). The dose in that study — 500 mg/kg in food — corresponds to a human equivalent of roughly 2,500–3,000 mg per day continuously, in a food matrix. No subsequent paper has replicated mouse lifespan extension with oral fisetin alone. This is a single unreplicated preclinical result.
The honest caveat. The leap from one mouse lifespan study, at a dose no human supplement approximates, to the marketing claim of "healthy aging support" in a daily human capsule is a significant extrapolation. The general "healthspan" language is defensible; the specific lifespan-extension implication is not.
What we still don't know
• Whether any of these preclinical benefits translate to human outcomes at capsule doses. This is the single largest gap in the fisetin evidence base and will be at least partially answered by AFFIRM and Hvidovre Fisetin HIGH readouts.
• Which dosing pattern optimises for which benefit. The Mayo Clinic pulsed protocol may be optimal for senescent-cell clearance but suboptimal for antioxidant effects, which may benefit from continuous exposure. This has not been formally tested.
• Whether benefits accrue and persist between pulses. The senolytic hypothesis assumes that senescent-cell clearance persists for weeks after each pulse. Human confirmation is pending.
• How fisetin’s effects compound with (or duplicate) those of other longevity interventions — quercetin, spermidine, urolithin A, exercise, caloric restriction. Stacking data are absent.
Bottom line
Fisetin has one of the most credible preclinical stories in the longevity supplement market and one of the smallest published human evidence bases. Every benefit on the product page has genuine biological support in mice and cells; almost none have peer-reviewed human confirmation. The most defensible reader position is that fisetin is a plausible bet on translation — a Tier 3 supplement with strong biology and unresolved clinical proof. That is a legitimate reason to take it; it is not the same thing as taking a supplement with documented human benefit. Anyone using fisetin should understand which tier of evidence they are betting on, and should track the AFFIRM, COVID-FIS, and Hvidovre readouts as they arrive. Our dedicated dosage article and pulse dosing article cover the practical protocol questions.
Frequently asked questions
Which fisetin benefit has the strongest evidence?
Preclinically, frailty and muscle preservation — because Murray 2025 produced effect sizes indistinguishable from gold-standard senolytic interventions in aged mice (2). Clinically, none: no human RCT has yet reported a positive endpoint for oral fisetin.
Is fisetin proven to make you live longer?
No. One 2018 mouse study reported modest median lifespan extension at a dose no human capsule approximates (1). No human study has tested this endpoint and it would be practically impossible to power one.
Does fisetin actually work in humans?
Unknown, based on published peer-reviewed randomised trials. Every major human trial is either running (AFFIRM, PROFFi, Fisetin HIGH) or has posted only preliminary results (COVID-FIS).
Which benefit should I expect first?
The most defensible expectation is that you feel nothing subjectively. Senescent-cell clearance, antioxidant activity, and SASP suppression are slow tissue-level processes. If you feel a rapid, dramatic subjective change from fisetin, the most likely explanations are placebo response or general flavonoid effects (GI tone, mood).
Is the benefit list on my supplement bottle honest?
It is honest about what fisetin has been studied for in preclinical research. It is not honest — in most cases — about the fact that the human clinical evidence has not yet arrived. Read benefit language on any fisetin product with that translation in mind.
References
1. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197652/
2. Murray KO, Mahoney SA, Venturini S, et al. Intermittent supplementation with fisetin improves physical function and decreases cellular senescence in skeletal muscle with aging. Aging Cell. 2025;24:e70114. https://doi.org/10.1111/acel.70114
3. Currais A, Farrokhi C, Dargusch R, et al. Fisetin reduces the impact of aging on behavior and physiology in the rapidly aging SAMP8 mouse. J Gerontol A Biol Sci Med Sci. 2018;73(3):299-307. https://pubmed.ncbi.nlm.nih.gov/28575152/
4. Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals. J Nutr Sci. 2022;11:e74. https://doi.org/10.1017/jns.2022.72
5. AFFIRM: Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women (NCT03430037). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03430037
6. COVID-FIS: Phase 2 Placebo-Controlled Pilot Study of Fisetin in Older Adults in Nursing Homes (NCT04537299). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04537299
7. Elsallabi O, Patruno A, Pesce M, et al. Fisetin as a senotherapeutic agent: biopharmaceutical properties and crosstalk between cell senescence and neuroprotection. Molecules. 2022;27(3):738. https://pmc.ncbi.nlm.nih.gov/articles/PMC8838024/
8. Sasaki M, Yasushi Y, Ohgomori T, et al. Fisetin promotes hair growth by augmenting TERT expression. Front Cell Dev Biol. 2020;8:566617. https://pmc.ncbi.nlm.nih.gov/articles/PMC7593534/
9. Wu PY, Lyu JL, Liu YJ, et al. Fisetin regulates Nrf2 expression and the inflammation-related signaling pathway to prevent UVB-induced skin damage in hairless mice. Int J Mol Sci. 2017;18(10):2118. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666800/
10. Zhang L, Wang H, Zhou Y, et al. Fisetin alleviates bleomycin-induced pulmonary fibrosis partly by rescuing alveolar epithelial cells from senescence. Front Pharmacol. 2020;11:553690. https://pmc.ncbi.nlm.nih.gov/articles/PMC7691425/
11. Wang C, Kim SY, Lee W, et al. Fisetin as a senotherapeutic compound in women’s reproductive health: evidence from in vitro to clinical studies. Antioxidants (Basel). 2025;14(9):1084. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12899922/
12. Prasath GS, Subramanian SP. Fisetin, a bioflavonoid ameliorates hyperglycemia in STZ-induced experimental diabetes in rats. Life Sci. 2011;89(3-4):145-152. https://pubmed.ncbi.nlm.nih.gov/21683720/